Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is an acquired immune-mediated inflammatory disorder of the peripheral nervous system. The pathologic hallmark of the disease is loss of the myelin sheath (the fatty covering that protects nerve fibers) of the peripheral nerves. First line treatment for CIDP includes corticosteroids (e.g. prednisone), plasmapheresis (plasma exchange) and intravenous immunoglobulin (IVIg) which may be prescribed alone or in combination with an immunosuppressant drug. IVIG and plasmapheresis have proven benefit in randomized, double-blind, placebo-controlled trials. A nubmer of case reprots, series and some phase II studies establish that amny patients with this condition respond with amelioration of symptoms or with a remission after a high dose therapy regimen with autologous stem cell transplantation.
S. Renaud, P. Fuhr, J. Halter, A. Gratwohl, A. Steck(2007) Autologous stem cell transplantation in therapy resistant chronic inflammatory demyelinating disease (CIDP) A phase II study. Call for patients Clinical Neurophysiology, Volume 118, Issue 2, Pages e4-e5
Oyama, Y., Sufit, R., Loh, Y., Statkute, L., Yaung, K., Quigley, K., Gonda, E., Spahovic, D., Bronesky, D., Burt, R. K. NONMYELOABLATIVE AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR REFRACTORY CIDP Neurology 2007 69: 1802-1803
Brannagan, T.H., III, Pradhan, A., Heiman-Patterson, T., Winkelman, A.C., Styler, M.J., Topolsky, D.L., Crilley, P.A., Schwartzman, R.J., Brodsky, I., Gladstone, D.E. High-dose cyclophosphamide without stem-cell rescue for refractory CIDP Neurology 2002 58: 1856-1858
H. W Axelson, G. Oberg, and H. Askmark Successful repeated treatment with high dose cyclophosphamide and autologous blood stem cell transplantation in CIDP BMJ Case Reports, February 2, 2009; 2009
Lehmann, Helmar C., Meyer zu Horste, Gerd, Kieseier, Bernd C., Hartung, Hans-Peter Review: Pathogenesis and treatment of immune-mediated neuropathies Therapeutic Advances in Neurological Disorders 2009 2: 261-281